AR111351A2 - FORMA CRISTALINA I DEL 17-a-PROPIONATO DE CORTEXOLONA, COMPOSICIÓN FARMACÉUTICA QUE LA CONTIENE Y SU EMPLEO EN EL TRATAMIENTO DE UNA PATOLOGÍA RELACIONADA CON EL APARATO UROGENITAL, ENDÓCRINO O DE LA PIEL Y/O ANEXOS DE ÉSTA - Google Patents

FORMA CRISTALINA I DEL 17-a-PROPIONATO DE CORTEXOLONA, COMPOSICIÓN FARMACÉUTICA QUE LA CONTIENE Y SU EMPLEO EN EL TRATAMIENTO DE UNA PATOLOGÍA RELACIONADA CON EL APARATO UROGENITAL, ENDÓCRINO O DE LA PIEL Y/O ANEXOS DE ÉSTA

Info

Publication number
AR111351A2
AR111351A2 ARP180100810A ARP180100810A AR111351A2 AR 111351 A2 AR111351 A2 AR 111351A2 AR P180100810 A ARP180100810 A AR P180100810A AR P180100810 A ARP180100810 A AR P180100810A AR 111351 A2 AR111351 A2 AR 111351A2
Authority
AR
Argentina
Prior art keywords
cortexolone
propionate
skin
urogenital
annexes
Prior art date
Application number
ARP180100810A
Other languages
English (en)
Inventor
Mauro Ajani
Luigi Moro
Original Assignee
Cassiopea Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40278805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR111351(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cassiopea Spa filed Critical Cassiopea Spa
Publication of AR111351A2 publication Critical patent/AR111351A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P33/00—Preparation of steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P33/00—Preparation of steroids
    • C12P33/005—Degradation of the lateral chains at position 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

Se refiere a formas cristalinas del 17-a-propionato de cortexolona, a una composición farmacéutica que la comprende y a su uso en el tratamiento de una patología relacionada con el aparato urogenital, endócrino, de la piel y/o de los anexos de la piel. Reivindicación 1: Forma cristalina I del 17-a-propionato de cortexolona, caracterizada porque el valor DRX es como se muestra en la figura 1 y/o el valor de DSC es como se muestra en la figura 2 y/o la IR es como se muestra en la figura 3.
ARP180100810A 2007-08-03 2018-04-03 FORMA CRISTALINA I DEL 17-a-PROPIONATO DE CORTEXOLONA, COMPOSICIÓN FARMACÉUTICA QUE LA CONTIENE Y SU EMPLEO EN EL TRATAMIENTO DE UNA PATOLOGÍA RELACIONADA CON EL APARATO UROGENITAL, ENDÓCRINO O DE LA PIEL Y/O ANEXOS DE ÉSTA AR111351A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001616A ITMI20071616A1 (it) 2007-08-03 2007-08-03 Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.

Publications (1)

Publication Number Publication Date
AR111351A2 true AR111351A2 (es) 2019-07-03

Family

ID=40278805

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP080103135A AR072235A1 (es) 2007-08-03 2008-07-18 Proceso enzimatico para obtener 17-alfa monoesteres de cortexolona y/o sus 9,11-dehidro derivados
ARP180100810A AR111351A2 (es) 2007-08-03 2018-04-03 FORMA CRISTALINA I DEL 17-a-PROPIONATO DE CORTEXOLONA, COMPOSICIÓN FARMACÉUTICA QUE LA CONTIENE Y SU EMPLEO EN EL TRATAMIENTO DE UNA PATOLOGÍA RELACIONADA CON EL APARATO UROGENITAL, ENDÓCRINO O DE LA PIEL Y/O ANEXOS DE ÉSTA
ARP180100811A AR111202A2 (es) 2007-08-03 2018-04-03 Formas cristalinas de cortexolona

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP080103135A AR072235A1 (es) 2007-08-03 2008-07-18 Proceso enzimatico para obtener 17-alfa monoesteres de cortexolona y/o sus 9,11-dehidro derivados

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP180100811A AR111202A2 (es) 2007-08-03 2018-04-03 Formas cristalinas de cortexolona

Country Status (25)

Country Link
US (9) US8785427B2 (es)
EP (5) EP3521298A1 (es)
JP (3) JP5646992B2 (es)
KR (1) KR101495192B1 (es)
CN (3) CN103450304B (es)
AR (3) AR072235A1 (es)
AU (1) AU2008285784B2 (es)
BR (1) BRPI0814163A2 (es)
CA (3) CA2691445C (es)
DK (4) DK2966175T3 (es)
ES (4) ES2732326T3 (es)
HR (4) HRP20140421T1 (es)
HU (3) HUE026206T2 (es)
IT (1) ITMI20071616A1 (es)
LT (1) LT2966175T (es)
MX (4) MX363701B (es)
NZ (3) NZ615953A (es)
PL (4) PL2966175T3 (es)
PT (4) PT2173891E (es)
RS (4) RS58950B1 (es)
RU (2) RU2482190C2 (es)
SI (4) SI2966175T1 (es)
TR (1) TR201909129T4 (es)
WO (1) WO2009019138A2 (es)
ZA (2) ZA201000587B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
ITMI20132157A1 (it) 2013-12-20 2015-06-21 Cosmo Dermatos Srl Cortexolone 17alfa-propionate for use in the treatment of skin wounds and/or atrophic skin disorders . cortexolone 17alfa-propionato per uso nel trattamento delle ferite della pelle e/o disordini atrofici della pelle.
EP3006453A1 (en) * 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
EP3108879A1 (en) * 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation
CN112028956A (zh) * 2020-09-10 2020-12-04 那路新 合成21-羟基-17-(1-氧代丙氧基)孕甾-4-烯-3,20-二酮的方法
DE112021004932T5 (de) 2020-10-19 2023-08-10 Industriale Chimica S.R.L. Verfahren zur herstellung von 21-(acetyloxy)-17-(1-oxopropoxy)-pregn-4-en-3,20-dion
IT202100008429A1 (it) 2021-04-06 2022-10-06 Farmabios Spa Processo per la preparazione di cortexolone 17α-propionato e sua nuova forma cristallina idrata
CN114410727B (zh) * 2022-01-25 2023-09-19 山东诺明康药物研究院有限公司 一种克拉考特酮的制备方法
CN115073546A (zh) * 2022-06-01 2022-09-20 浙江神洲药业有限公司 一种新型雄激素受体抑制剂的制备方法
CN115466301A (zh) * 2022-08-29 2022-12-13 扬州奥锐特药业有限公司 一种甾体化合物，其晶型a及它们的制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB791771A (en) 1954-07-29 1958-03-12 Merck & Co Inc Steroid compounds
US2985650A (en) 1958-05-28 1961-05-23 Syntex Sa 6alpha-ammonio-derivatives of 11-keto cortical hormones
CH429716A (de) 1961-06-24 1967-02-15 Vismara Francesco Spa Verfahren zur Herstellung von 17a-Acyloxy-21-hydroxy-Steroiden
NL6605514A (es) * 1966-04-25 1967-10-26
NL6605515A (es) * 1966-04-25 1967-10-26
US3780177A (en) 1967-06-16 1973-12-18 Warner Lambert Co 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
US3733318A (en) 1972-03-23 1973-05-15 Syntex Corp 21-orthoesters of cortical steroids and methods of preparing same
JPS5910799B2 (ja) * 1975-07-15 1984-03-12 大正製薬株式会社 プレグナン系ステロイド １７−エステル類の製法
GB2109817B (en) 1981-11-18 1985-07-03 Ibm Electrodeposition of chromium
DE3243482A1 (de) 1982-11-22 1984-05-24 Schering AG, 1000 Berlin und 4709 Bergkamen Neue 6(alpha)-methylkortikoide, ihre herstellung und verwendung
DE3402330A1 (de) 1984-01-20 1985-07-25 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US4920216A (en) 1987-05-28 1990-04-24 The Trustees Of Columbia In The City Of New York Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates
US5264428A (en) 1990-02-16 1993-11-23 Kanoldt Arzneimittel Gmbh Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases
JPH08135789A (ja) 1994-11-09 1996-05-31 Komatsu Ltd 車両の油圧式駆動装置の変速装置およびその変速制御方法
DE19653730C2 (de) * 1996-12-11 1999-06-24 Schering Ag Immobilisierte Proteine aus Rohextrakt und deren Verwendung zur Umsetzung von Estern
CA2263940A1 (en) 1997-06-25 1998-12-30 Teijin Limited Vitamin d3 derivatives and remedies for inflammatory respiratory diseases prepared from the same
ATE404575T1 (de) 2001-05-22 2008-08-15 Pfizer Prod Inc Neue kristallforme von azithromycin
ITMI20011762A1 (it) 2001-08-10 2003-02-10 Cosmo Spa Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
WO2004060347A2 (en) 2002-09-03 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003080042A1 (fr) 2002-03-27 2003-10-02 Shionogi & Co., Ltd. Inhibiteur de decomposition pour matrice extracellulaire de cartilage
ES2273061T3 (es) 2002-08-02 2007-05-01 Schering Aktiengesellschaft Agentes moduladores de receptores de progesterona con actividad antigonadotropa elevada para el control de fertilidad femenina y para la terapia por reemplazo hormonal.
AU2003278744B2 (en) 2002-08-28 2010-07-29 Harbor Biosciences, Inc. Therapeutic treatment methods
AR043444A1 (es) 2003-03-05 2005-07-27 Merck Frosst Canada Inc Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2
US20050008704A1 (en) 2003-07-11 2005-01-13 Ray Anup Kumar Pharmaceutical composition for solubility enhancement of hydrophobic drugs
JP2008189549A (ja) 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
ITMI20051695A1 (it) * 2005-09-14 2007-03-15 Cosmo Spa Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
WO2012078649A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
ITMI20132157A1 (it) 2013-12-20 2015-06-21 Cosmo Dermatos Srl Cortexolone 17alfa-propionate for use in the treatment of skin wounds and/or atrophic skin disorders . cortexolone 17alfa-propionato per uso nel trattamento delle ferite della pelle e/o disordini atrofici della pelle.
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation

Also Published As

Publication number Publication date
EP2503005A2 (en) 2012-09-26
EP2503005A3 (en) 2012-10-03
US10166245B2 (en) 2019-01-01
PT2966175T (pt) 2019-06-27
US20160326210A1 (en) 2016-11-10
ZA201000587B (en) 2011-04-28
RU2482190C2 (ru) 2013-05-20
CA2871025C (en) 2016-05-24
PT2173891E (pt) 2014-05-19
US10716796B2 (en) 2020-07-21
EP3521298A1 (en) 2019-08-07
RU2012113839A (ru) 2013-10-20
US20140179654A1 (en) 2014-06-26
DK2173891T3 (da) 2014-04-28
JP6174645B2 (ja) 2017-08-02
ZA201100133B (en) 2014-03-26
PL2503004T3 (pl) 2016-05-31
CN103450304B (zh) 2016-05-25
NZ615953A (en) 2015-03-27
WO2009019138A3 (en) 2009-10-15
EP2966175B1 (en) 2019-05-08
HRP20140421T1 (hr) 2014-06-06
RS54361B1 (en) 2016-04-28
DK2966175T3 (da) 2019-07-01
LT2966175T (lt) 2019-08-26
EP2503004A1 (en) 2012-09-26
US8785427B2 (en) 2014-07-22
JP6108944B2 (ja) 2017-04-05
KR20100044845A (ko) 2010-04-30
AU2008285784B2 (en) 2014-06-26
AU2008285784A1 (en) 2009-02-12
HUE026507T2 (hu) 2016-06-28
US11938141B2 (en) 2024-03-26
SI2966175T1 (sl) 2019-08-30
CA2691445C (en) 2017-11-28
AR111202A2 (es) 2019-06-12
CN104861023A (zh) 2015-08-26
CN101743316B (zh) 2013-09-04
JP2016014045A (ja) 2016-01-28
JP2013163683A (ja) 2013-08-22
RS53310B (en) 2014-10-31
CN104861023B (zh) 2017-04-12
DK2503004T3 (en) 2015-11-02
AR072235A1 (es) 2010-08-18
PL2966175T3 (pl) 2019-11-29
HRP20151174T1 (hr) 2015-12-04
EP2173891B1 (en) 2014-02-12
PT2503005E (pt) 2015-12-09
RS58950B1 (sr) 2019-08-30
BRPI0814163A2 (pt) 2015-01-20
US20160051566A1 (en) 2016-02-25
RS54354B1 (en) 2016-04-28
RU2010107599A (ru) 2011-09-10
HUE026206T2 (hu) 2016-05-30
US20220280531A1 (en) 2022-09-08
JP2010535173A (ja) 2010-11-18
WO2009019138A2 (en) 2009-02-12
TR201909129T4 (tr) 2019-07-22
US9433628B2 (en) 2016-09-06
NZ600767A (en) 2013-11-29
SI2173891T1 (sl) 2014-06-30
SI2503004T1 (sl) 2015-12-31
DK2503005T3 (en) 2015-11-16
US20110092472A1 (en) 2011-04-21
MX2010001256A (es) 2010-05-17
PT2503004E (pt) 2015-12-09
NZ599437A (en) 2013-11-29
US10159682B2 (en) 2018-12-25
HRP20191143T1 (hr) 2019-09-20
KR101495192B1 (ko) 2015-02-25
CA2871025A1 (en) 2009-02-12
MX363701B (es) 2019-03-29
US20230104965A1 (en) 2023-04-06
EP2173891A2 (en) 2010-04-14
RU2599452C2 (ru) 2016-10-10
US20200155572A1 (en) 2020-05-21
EP2503004B1 (en) 2015-09-02
US9486458B2 (en) 2016-11-08
HRP20151298T1 (hr) 2016-01-01
EP2966175A1 (en) 2016-01-13
MX363238B (es) 2019-03-15
EP2503005B1 (en) 2015-09-02
CA2691445A1 (en) 2009-02-12
ES2732326T3 (es) 2019-11-21
CA2871039A1 (en) 2009-02-12
PL2503005T3 (pl) 2016-05-31
HUE044237T2 (hu) 2019-10-28
CN101743316A (zh) 2010-06-16
US20160324873A1 (en) 2016-11-10
ES2551910T3 (es) 2015-11-24
PL2173891T3 (pl) 2014-07-31
CA2871039C (en) 2017-11-28
JP5646992B2 (ja) 2014-12-24
US20190083511A1 (en) 2019-03-21
ITMI20071616A1 (it) 2009-02-04
CN103450304A (zh) 2013-12-18
MX2019003639A (es) 2019-06-17
ES2554934T3 (es) 2015-12-28
SI2503005T1 (sl) 2015-12-31
US11207332B2 (en) 2021-12-28
ES2462946T3 (es) 2014-05-26

Similar Documents

Publication Publication Date Title
AR111351A2 (es) FORMA CRISTALINA I DEL 17-a-PROPIONATO DE CORTEXOLONA, COMPOSICIÓN FARMACÉUTICA QUE LA CONTIENE Y SU EMPLEO EN EL TRATAMIENTO DE UNA PATOLOGÍA RELACIONADA CON EL APARATO UROGENITAL, ENDÓCRINO O DE LA PIEL Y/O ANEXOS DE ÉSTA
ECSP11011243A (es) Agonistas y antagonistas de los receptores s1p5 y metodos de usos similares aplicaciones relacionadas
CL2015003117A1 (es) Modificaciones en la estructura cristalina
GT201000008A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
ECSP14013171A (es) Composición limpiadora
HN2011002406A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
UY33598A (es) Imidazopiridazinas sustituidas
GT201400043A (es) Imidazopiridazinas sustituidas con amino
CL2015003135A1 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso.
CR20110596A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
UY31228A1 (es) Ariloxazoles sustituidos y su uso
CO2017011483A2 (es) Pajita comestible para consumir bebidas
PE20191149A1 (es) Uso farmaceutico de una composicion que contiene pirfenidona de liberacion prolongada (pfd-lp) para la reversion y tratamiento de la esteatohepatitis humana (nafld/nash)
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
CL2008002984A1 (es) Composicion farmaceutica que comprende micofenolato sodico y su uso para el tratamiento y/o prevencion en enfermedades autoinmunes tales como el rechazo de aloinjertos o xenoinjertos de organos, celulas o tejidos y como antiinflamatorio.
PE20151759A1 (es) Imidazopiridazinas sustituidas
ECSP17038893A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
NI201600006A (es) Pirazolo-piridinaminas sustituidas
CO2018008449A2 (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
HN2010000128A (es) Imidazoles sustituidos con heterociclilamida
SV2018005783A (es) 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]piridin-3(2h)-onas y 2,5,6,7-tetrahydro-3h-pyrrolo[2,1-c][1,2,4]triazol-3-ones sustituidas su uso
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CL2012003497A1 (es) Procedimiento para preparar el compuesto diácido 3,6,9-triaza-3,6,9-tris(carboximetil)-4-(4-etoxibencil)-undecanoico cristalino; su uso para preparar una formulación galénica del complejo de gadolinio de diacido 3,6,9-triaza-3,6,9-tris(carboximetil)-4-(4-etoxibencil)-undecanoico; y el compuesto con una pureza superior al 99%.